{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:06:21Z","timestamp":1762376781327},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>Adverse drug reactions (ADRs) are a serious burden and can negatively impact patient quality of life. One of these ADRs, anthracycline-induced cardiotoxicity (ACT), occurs in up to 65% of treated patients and can lead to congestive heart failure. Pharmacogenetic studies have helped to reveal the mechanisms of ACT and, consequently, inform current strategies to prevent ACT in the clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Many pharmacogenetic studies have been conducted for ACT, but few have led to the development of clinical practice guidelines and clinical genetic testing for ACT. This is, in part, because of lack of replication in independent patient cohorts and\/or validation of an affected biological pathway. Recent advances in pharmacogenetic studies have been made through the use of novel methods that directly implicate dysregulated genes and perturbed biological pathways in response to anthracycline treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Furthering the understanding of the genetics and altered biological pathways of ACT through these novel methods can inform clinical treatment strategies and enable refinement of current clinical practice guidelines. This can therefore lead to improvement in clinical pharmacogenetic testing for further reduction of the incidence of ACT in pediatric cancer patients taking anthracyclines.<\/jats:p><\/jats:sec>","DOI":"10.1097\/mop.0000000000000935","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T02:02:32Z","timestamp":1597370552000},"page":"646-653","source":"Crossref","is-referenced-by-count":2,"title":["Prevention of adverse drug effects: a pharmacogenomic approach"],"prefix":"10.1097","volume":"32","author":[{"given":"Erika N.","family":"Scott","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, Faculty of Medicine, University of British Columbia"},{"name":"British Columbia Children's Hospital Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafar S.","family":"Hasbullah","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Faculty of Medicine, University of British Columbia"},{"name":"British Columbia Children's Hospital Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce C.","family":"Carleton","sequence":"additional","affiliation":[{"name":"British Columbia Children's Hospital Research Institute"},{"name":"Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia"},{"name":"Pharmaceutical Outcomes Programme, British Columbia Children's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin J.D.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Faculty of Medicine, University of British Columbia"},{"name":"British Columbia Children's Hospital Research Institute"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA Am Med Assoc"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1060028018765159","article-title":"Cost of prescription drug-related morbidity and mortality","volume":"52","author":"Watanabe","year":"2018","journal-title":"Ann Pharmacother"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdf118","article-title":"Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review","volume":"13","author":"Kremer","year":"2002","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1389200216888150915112039","article-title":"Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines","volume":"16","author":"Edwardson","year":"2015","journal-title":"Curr Drug Metab"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.yjmcc.2006.06.009","article-title":"New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics","volume":"41","author":"Tokarska-Schlattner","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12012-007-0008-2","article-title":"Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis","volume":"7","author":"Wallace","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-2143(96)90095-5","article-title":"Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction","volume":"127","author":"Link","year":"1996","journal-title":"J Lab Clin Med"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fphar.2014.00025","article-title":"The role of iron in anthracycline cardiotoxicity","volume":"5","author":"Gammella","year":"2014","journal-title":"Front Pharmacol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.117.310965","article-title":"Opportunities and challenges in cardiovascular pharmacogenomics: from discovery to implementation","volume":"122","author":"Roden","year":"2018","journal-title":"Circ Res"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-019-0127-1","article-title":"Benefits and limitations of genome-wide association studies","volume":"20","author":"Tam","year":"2019","journal-title":"Nat Rev Genet"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J Clin Oncol"},{"key":"R20-20230918","first-page":"1246","article-title":"Common regulatory variation impacts gene expression in a cell type-dependent manner","volume":"325","author":"Dimas","year":"2009","journal-title":"Sci Am Assoc Adv Sci"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"e10693","DOI":"10.1371\/journal.pone.0010693","article-title":"Genetics and beyond: the transcriptome of human monocytes and disease susceptibility","volume":"5","author":"Zeller","year":"2010","journal-title":"PLoS One Public Libr Sci"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/jpet.104.081968","article-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S)","volume":"313","author":"Krishnaswamy","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children: genetic variants associated with ACT","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ng.3374","article-title":"A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer","volume":"47","author":"Aminkeng","year":"2015","journal-title":"Nat Genet"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cell.2019.02.032","article-title":"Genomic analysis in the age of human genome sequencing","volume":"177","author":"Lappalainen","year":"2019","journal-title":"Cell"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity: genetic testing recommendations for anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41588-019-0385-z","article-title":"Opportunities and challenges for transcriptome-wide association studies","volume":"51","author":"Wainberg","year":"2019","journal-title":"Nat Genet"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41467-018-03621-1","article-title":"Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics","volume":"9","author":"Barbeira","year":"2018","journal-title":"Nat Commun"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/ng.3506","article-title":"Integrative approaches for large-scale transcriptome-wide association studies","volume":"48","author":"Gusev","year":"2016","journal-title":"Nat Genet"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"e1007889","DOI":"10.1371\/journal.pgen.1007889","article-title":"Integrating predicted transcriptome from multiple tissues improves association detection","volume":"15","author":"Barbeira","year":"2019","journal-title":"PLoS Genet"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nature24277","article-title":"Genetic effects on gene expression across human tissues","volume":"550","year":"2017","journal-title":"Nature"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/nprot.2008.92","article-title":"Generation of human-induced pluripotent stem cells","volume":"3","author":"Park","year":"2008","journal-title":"Nat Protoc"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat Med"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"e33480","DOI":"10.7554\/eLife.33480","article-title":"Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes","volume":"7","author":"Knowles","year":"2018","journal-title":"eLife"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.taap.2018.07.020","article-title":"RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin","volume":"356","author":"Reyes","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/cvr\/cvz018","article-title":"hiPSCs in cardio-oncology: deciphering the genomics","volume":"115","author":"Pinheiro","year":"2019","journal-title":"Cardiovasc Res"},{"key":"R38-20230918","doi-asserted-by":"crossref","DOI":"10.1007\/s12265-020-09962-x","article-title":"Human in vitro models for assessing the genomic basis of chemotherapy-induced cardiovascular toxicity","author":"Pinheiro","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jat.3007","article-title":"Cardiotoxicity evaluation of anthracyclines in zebrafish (Danio rerio)","volume":"35","author":"Han","year":"2015","journal-title":"J Appl Toxicol"},{"key":"R40-20230918","first-page":"1642684","article-title":"Using zebrafish for investigating the molecular mechanisms of drug-induced cardiotoxicity","volume":"2018","author":"Zakaria","year":"2018","journal-title":"BioMed Res Int Hindawi"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature12111","article-title":"The zebrafish reference genome sequence and its relationship to the human genome","volume":"496","author":"Howe","year":"2013","journal-title":"Nature"},{"key":"R42-20230918","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88797","article-title":"A modifier screen identifies DNAJB6 as a cardiomyopathy susceptibility gene","author":"Ding","year":"2016","journal-title":"JCI Insight"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.58.4.7","article-title":"International Union of Pharmacology. LXIII. Retinoid x receptors","volume":"58","author":"Germain","year":"2006","journal-title":"Pharmacol Rev"},{"key":"R44-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.12.003","article-title":"Retinoic acid receptors: From molecular mechanisms to cancer therapy","volume":"41","author":"di Masi","year":"2015","journal-title":"Mol Aspects Med"},{"key":"R45-20230918","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/FPC.0000000000000302","article-title":"Genome-wide association study of cardiotoxicity in the NCCTG N9831 (alliance) adjuvant trastuzumab trial","volume":"27","author":"Serie","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R46-20230918","doi-asserted-by":"crossref","first-page":"eaay2939","DOI":"10.1126\/sciadv.aay2939","article-title":"Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity","volume":"6","author":"Ma","year":"2020","journal-title":"Sci Adv"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bph.13377","article-title":"All-trans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathway","volume":"173","author":"Yang","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R48-20230918","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1751-7133.2011.00278.x","article-title":"Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol","volume":"18","author":"Pellicori","year":"2012","journal-title":"Congest Heart Fail"},{"key":"R49-20230918","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-017-3004-z","article-title":"Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin","volume":"96","author":"Rodr\u00edguez-Veiga","year":"2017","journal-title":"Ann Hematol"},{"key":"R50-20230918","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1093\/bioinformatics\/bty475","article-title":"HUME: large-scale detection of causal genetic factors of adverse drug reactions","volume":"34","author":"Mansouri","year":"2018","journal-title":"Bioinformatics"},{"key":"R51-20230918","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cell.2020.03.022","article-title":"How machine learning will transform biomedicine","volume":"181","author":"Goecks","year":"2020","journal-title":"Cell"},{"key":"R52-20230918","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/CBI20110264","article-title":"ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia","volume":"36","author":"Semsei","year":"2012","journal-title":"Cell Biol Int"},{"key":"R53-20230918","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12885-018-4629-6","article-title":"Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma","volume":"18","author":"S\u00e1gi","year":"2018","journal-title":"BMC Cancer"},{"key":"R54-20230918","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br J Haematol"},{"key":"R55-20230918","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/tpj.2015.63","article-title":"Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia","volume":"16","author":"Krajinovic","year":"2016","journal-title":"Pharmacogenom J"},{"key":"R56-20230918","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/10428194.2016.1231405","article-title":"Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia","volume":"58","author":"Meg\u00edas-Vericat","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R57-20230918","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.15.61","article-title":"Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children","volume":"16","author":"Visscher","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R58-20230918","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes: a report from the Children's Oncology Group","volume":"30","author":"Blanco","year":"2011","journal-title":"J Clin Oncol"},{"key":"R59-20230918","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/cncr.23534","article-title":"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer","volume":"112","author":"Blanco","year":"2008","journal-title":"Cancer"},{"key":"R60-20230918","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/cncr.26472","article-title":"Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma","volume":"118","author":"Windsor","year":"2012","journal-title":"Cancer"},{"key":"R61-20230918","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/cncr.28256","article-title":"Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia","volume":"119","author":"Lipshultz","year":"2013","journal-title":"Cancer"},{"key":"R62-20230918","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428190903177212","article-title":"Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood","volume":"50","author":"Raji\u0107","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R63-20230918","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.2013.50.3557","article-title":"Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the Children's Oncology Group","volume":"32","author":"Wang","year":"2014","journal-title":"J Clin Oncol"},{"key":"R64-20230918","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1038\/s41598-017-09517-2","article-title":"Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term childhood cancer survivors","volume":"7","author":"Hildebrandt","year":"2017","journal-title":"Sci Rep"},{"key":"R65-20230918","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2015.63.4550","article-title":"CELF4 variant and anthracycline-related cardiomyopathy: a Children's Oncology Group Genome-Wide association study","volume":"34","author":"Wang","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T20:03:26Z","timestamp":1723406606000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000935","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"type":"print","value":"1040-8703"},{"type":"electronic","value":"1531-698X"}],"subject":[],"published":{"date-parts":[[2020,8,11]]}}}